Loi Sherene, Salgado Roberto, Adams Sylvia, Pruneri Giancarlo, Francis Prudence A, Lacroix-Triki Magali, Joensuu Heikki, Dieci Maria Vittoria, Badve Sunil, Demaria Sandra, Gray Robert, Munzone Elisabetta, Drubay Damien, Lemonnier Jerome, Sotiriou Christos, Kellokumpu-Lehtinen Pirkko Liisa, Vingiani Andrea, Gray Kathryn, André Fabrice, Denkert Carsten, Piccart Martine, Roblin Elvire, Michiels Stefan
Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
Sir Peter MacCallum Cancer Department of Oncology, University of Melbourne, Melbourne, VIC, Australia.
NPJ Breast Cancer. 2022 Jan 11;8(1):3. doi: 10.1038/s41523-021-00362-1.
The importance of integrating biomarkers into the TNM staging has been emphasized in the 8 Edition of the American Joint Committee on Cancer (AJCC) Staging system. In a pooled analysis of 2148 TNBC-patients in the adjuvant setting, TILs are found to strongly up and downstage traditional pathological-staging in the Pathological and Clinical Prognostic Stage Groups from the AJJC 8 edition Cancer Staging System. This suggest that clinical and research studies on TNBC should take TILs into account in addition to stage, as for example patients with stage II TNBC and high TILs have a better outcome than patients with stage I and low TILs.
美国癌症联合委员会（AJCC）分期系统第8版强调了将生物标志物纳入TNM分期的重要性。在一项对2148例辅助治疗环境下三阴乳腺癌患者的汇总分析中，发现肿瘤浸润淋巴细胞（TILs）在AJJC第8版癌症分期系统的病理和临床预后分期组中显著上调和下调传统病理分期。这表明，三阴乳腺癌的临床和研究应在分期之外考虑肿瘤浸润淋巴细胞，例如，II期三阴乳腺癌且肿瘤浸润淋巴细胞水平高的患者比I期且肿瘤浸润淋巴细胞水平低的患者预后更好。
